Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate

Noris Rodriguez, Brian N. Bailey, Michael B. Martin, Eric Oldfield, Julio A. Urbina, Roberto Docampo

Research output: Contribution to journalArticlepeer-review


The effects in vivo of the bisphosphonate drug pamidronate, used in bone resorption therapy, were investigated in an experimental model of cutaneous leishmaniasis. Pamidronate at an intraperitoneal dose of 10 mg/kg/day for 5 days effects a radical cure of cutaneous leishmaniasis in Balb/c mice, as evidenced by long-term disappearance of lesions; disappearance of amastigotes in lesion sites, as determined by histopathological analysis and cultivation of material obtained from lesions; and polymerase chain reaction analysis of necropsy material, using probes specific for kinetoplast DNA. Pamidronate is, therefore, a new lead compound for the synthesis of drugs effective against cutaneous leishmaniasis.

Original languageEnglish (US)
Pages (from-to)138-140
Number of pages3
JournalJournal of Infectious Diseases
Issue number1
StatePublished - Jul 1 2002

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases


Dive into the research topics of 'Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate'. Together they form a unique fingerprint.

Cite this